ArticleIn vitro cellular & developmental biology. Animal2022
LncRNA NRON negatively regulates cisplatin-induced cell apoptosis via downregulating miR-31 in esophageal squamous cell carcinomas.
Article in In vitro cellular & developmental biology. Animal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Roles of long non‑coding RNAs in esophageal cell squamous carcinoma (Review).International journal of molecular medicine · 2024Review
- LncRNA NRON promotes tumorigenesis by enhancing MDM2 activity toward tumor suppressor substrates.The EMBO journal · 2023Article
- The roles and mechanisms of the lncRNA-miRNA axis in the progression of esophageal cancer: a narrative review.Journal of thoracic disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
LncRNA non-coding repressor of NFAT (NRON) can promote bladder cancer and suppress liver cancer, while its role in esophageal squamous cell carcinoma (ESCC) is unknown. We analyzed its involvement in ESCC. NRON and miR-31 expression in plasma before and after cisplatin treatment was detected using RT-qPCR. The correlation between NRON and miR-31 was analyzed by linear regression. Expression of NRON and miR-31 in ESCC cells was also analyzed using RT-qPCR. Overexpression of NRON and miR-31 was achieved in ESCC cells to explore their interaction. Cell apoptosis induced by cisplatin was studied using cell apoptosis assay. NRON was highly expressed in ESCC and further upregulated after cisplatin treatment. MiR-31 was downregulated in ESCC and inversely correlated with NRON. In ESCC cells, NRON overexpression decreased miR-31 expression, while miR-31 failed to alter NRON expression. Cisplatin treatment promoted NRON expression and inhibited miR-31 expression. Under cisplatin treatment, cell apoptosis was inhibited after NRON overexpression and increased after miR-31 overexpression. Moreover, NRON inhibited the effect of miR-31 on cell apoptosis. NRON might promote the development of cisplatin resistance via downregulating miR-31 in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.